New Proton Therapy Trial Launches in Philadelphia
The feasibility study treats patients with inoperable head and neck cancers using a new radiation delivery method.
Updated on Oct. 21, 2026 in Cancer
Penn Medicine has initiated the C-FLASH-01 human feasibility trial, treating its first patient with fractionated ConformalFLASH proton therapy. This study investigates a new approach for patients with head and neck cancers that cannot be surgically removed.
Why it matters
For patients whose head and neck cancers are not amenable to surgery, this trial assesses the potential for a new radiation delivery method. It represents an early-stage effort to refine treatment precision for complex cases.
The C-FLASH-01 clinical trial is a human feasibility study evaluating fractionated ConformalFLASH proton therapy. As the research is in its preliminary stages with the first patient treated, the therapy's overall performance remains under investigation.
The players
Penn Medicine
An academic medical center that is serving as the clinical trial site.
IBA
A developer of particle accelerator technology that is overseeing the clinical trial.
FDA
The federal agency responsible for authorizing the Investigational Device Exemption for this trial.
The details
The treatment utilizes Bragg peak proton beams to deliver radiation specifically targeted to tumor sites. This approach incorporates precision-milled patient-specific apertures and 3D-printed devices to guide the proton delivery. The study is conducted under an Investigational Device Exemption authorized by the FDA to test the feasibility of this radiotherapy configuration.
Timeline
October 21, 2026: The first patient received treatment in the C-FLASH-01 clinical trial.
Health Landscape
The C-FLASH-01 clinical trial represents an evolution in radiotherapy techniques for head and neck cancer patients. The study marks an early exploration of ConformalFLASH technology, building on the long-term medical focus on refining proton therapy delivery precision.
This trial is limited to specific patients with head and neck cancer who are not candidates for surgery. If you or a loved one are exploring radiation options, it is worth discussing the status of such clinical trials with an oncologist.
The takeaway
The C-FLASH-01 trial is an early step in testing whether a specialized proton therapy delivery system can safely treat complex, inoperable head and neck tumors. Patients interested in emerging treatment options should speak with their care team about relevant trial enrollment criteria.
Further reading
For more on advancements in oncology, explore the latest research in our Cancer section.
